2023 World Conference on Lung Cancer (Posters)-EP10.01. Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice.

EP10.01. Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice. - PDF(Slides)

Back to course

Pdf Summary

This study evaluated the occurrence of pneumonitis in lung cancer patients treated with Osimertinib, a targeted therapy drug. The researchers conducted a retrospective cohort study of 100 patients treated with Osimertinib at two medical centers. They collected patient demographics, tumor genetics, radiographic findings, and treatment-related variables.<br /><br />Six out of the 100 patients developed pneumonitis while on Osimertinib. The median age of these patients was 63 years, and the median duration on Osimertinib was 7.54 months. The time to pneumonitis was around 1.94 months. The median survival of patients with pneumonitis was 3.63 months.<br /><br />The study also found that 12 out of 84 patients who did not develop respiratory symptoms on Osimertinib had new infiltrates on pre-progression CT imaging. However, there was no clinical or radiographic suspicion of pneumonitis in these cases. None of the patients in the study received a lung biopsy to confirm pneumonitis due to the rapid development of hypoxemia.<br /><br />The researchers concluded that pneumonitis induced by Osimertinib is a fulminant and rapidly fatal complication. Biopsy is not feasible for these patients due to their deteriorating condition. They also found that asymptomatic inflammatory changes observed on CT lung imaging are not predictive of pneumonitis. Therefore, Osimertinib can still be considered safe to use in patients when such changes are incidentally identified in the absence of worsening respiratory symptoms.<br /><br />Overall, this study provides insights into the occurrence and characteristics of pneumonitis induced by Osimertinib in a real-world clinical practice setting.

Asset Subtitle

Shawn Ali

Meta Tag

Speaker Shawn Ali

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

pneumonitis

lung cancer

Osimertinib

targeted therapy

retrospective cohort study

patient demographics

tumor genetics

radiographic findings

treatment-related variables

respiratory symptoms